Results 191 to 200 of about 95,049 (250)
ABSTRACT Coronavirus disease 2019 (COVID‐19) survivors frequently experience a wide range of symptoms known as post‐acute sequelae of SARS‐CoV‐2 (PASC) or long COVID. Importantly, complications arising from microvascular dysfunction, blood‐brain barrier (BBB) disruption, and chronic neuroinflammation have been implicated in driving PASC within the ...
Arpan Acharya +7 more
wiley +1 more source
From Oral Candidiasis to Candidemia: A Review of Superficial to Invasive Progression
Recent and limited evidence indicates that oral candidiasis can disseminate Candida albicans throughout the body, leading to invasive candidiasis, such as candidemia, a life‐threatening infection. Considering antifungal resistance and global outbreaks of emergent non‐albicans Candida and related yeasts, murine models help understand dissemination ...
Julia Robledo Jerez +3 more
wiley +1 more source
Mycobacterium tuberculosis–host interactions and infection outcomes. Following initial infection, alveolar macrophages phagocytose the pathogen, prompting the recruitment of innate immune cells including neutrophils, NK cells, and interstitial macrophages.
Xiaojuan Zhang +3 more
wiley +1 more source
Nucleotide Metabolism in Health and Disease
Nucleotide metabolism, including de novo synthesis, salvage pathways, and catabolism, when dysregulated contributes to cancer, immune disorders, metabolic and urological diseases, and radiation injury. Metabolites such as adenosine, cGAMP, NAD, and cAMP and enzymes like RNR are promising therapeutic targets and biomarkers.
Xiaoying Zhao +7 more
wiley +1 more source
ABSTRACT Protein S‐palmitoylation, a reversible lipid modification, plays critical roles in regulating protein function and localization. However, its comprehensive role in the rapid reprogramming of macrophages during early immune responses remains incompletely understood.
Hyojung Kim +4 more
wiley +1 more source
ABSTRACT Interindividual variability (IIV) in drug response complicates both fixed‐dose design and individualized therapy. Understanding how pharmacokinetic (PK) and pharmacodynamic (PD) processes jointly shape this variability is essential, particularly in combination therapy, where multiple interacting pathways influence outcomes. This study employed
Kuteesa R. Bisaso +3 more
wiley +1 more source
Medications That Regulate Pregnane X Receptor: A Systematic Review of Current Evidence
PRISMA 2020 flow diagram of study selection for this systematic review of medications that regulate the pregnane X receptor (PXR), from 12 236 records screened to 101 included studies. ABSTRACT The pregnane X receptor (PXR) gene encodes a ligand‐activated protein involved with the metabolism and excretion of drugs, toxins, and other xenobiotics.
Petra Czarniak +4 more
wiley +1 more source
Recent Advances in the Molecular Mechanisms of Bacterial Anti‐Phage Defence Systems
Panoptes as an example for an antiphage system consists of OptS producing a cyclic dinucleotide that prevents activation of OptE, a transmembrane protein. Phage T4 infection introduces the sponge protein Acb2 that adsorbs the cyclic dinucleotide thus activating OptE which disrupts the cell membrane aborting phage infection.
Harald Brüssow
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
New England Journal of Medicine, 1998
Inhibitors of human immunodeficiency virus (HIV)–encoded protease, combined with nucleoside analogues with antiretroviral activity, cause profound and sustained suppression of viral replication, reduce morbidity, and prolong life in patients with HIV infection.1–3 Recent guidelines recommend that initial treatment of all HIV-infected patients include ...
Charles Flexner, Flexner Charles
exaly +9 more sources
Inhibitors of human immunodeficiency virus (HIV)–encoded protease, combined with nucleoside analogues with antiretroviral activity, cause profound and sustained suppression of viral replication, reduce morbidity, and prolong life in patients with HIV infection.1–3 Recent guidelines recommend that initial treatment of all HIV-infected patients include ...
Charles Flexner, Flexner Charles
exaly +9 more sources
Inhibition of HIV‐2 Protease by HIV‐1 Protease Inhibitors in Clinical Use
Chemical Biology and Drug Design, 2008Over the past 10 years, protease inhibitors have been a key component in antiretroviral therapies for HIV/AIDS. While the vast majority of HIV/AIDS cases in the world are due to HIV‐1, HIV‐2 infection must also be addressed. HIV‐2 is endemic to Western Africa, and has also appeared in European countries such as Portugal, Spain, and Estonia.
Ernesto Freire
exaly +3 more sources

